Voices
Mostafa Faisal: Venetoclax Plus Azacitidine in Monocytic and Monocytic-Like Acute Myeloid Leukemia
Mostafa Faisal/LinkedIn

Mostafa Faisal: Venetoclax Plus Azacitidine in Monocytic and Monocytic-Like Acute Myeloid Leukemia

Mostafa Faisal, Adjunct Assistant Professor at Alfaisal University, shared a post on X about a paper by Marina Konopleva et al. published in American Journal of Hematology:

“Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia, Including AML-M4 and AML-M5, Treated With Venetoclax Plus Azacitidine.

Ven–Aza in monocytic AML

CR/CRi: ~60% monocytic versus ~70% non-monocytic

OS: Similar overall (~13–15 mo)

Key driver: Mutations > phenotype

  • NPM1+ monocytic → OS 46.3 mo
  • N/KRAS+ monocytic → OS 3.4 mo

Biology: ↓BCL2, ↑MCL1 in monocytic AML.”

Title: Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia, Including AML-M4 and AML-M5, Treated With Venetoclax Plus Azacitidine

Authors: Marina Konopleva, Courtney DiNardo, Yan Sun, Paul Jung, Sanam Loghavi, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel Pollyea

Read the Full Article.

Mostafa Faisal: Venetoclax Plus Azacitidine in Monocytic and Monocytic-Like Acute Myeloid Leukemia

More posts featuring Mostafa Faisal on OncoDaily.

American Journal of Hematology Brenda Chyla cancer Courtney DiNardo Daniel Pollyea Jalaja Potluri Marina Konopleva Monique Dail Mostafa Faisal OncoDaily Oncology Paul Jung Sanam Loghavi Yan Sun